TMEM68 Inhibitors
TMEM68 inhibitors include a range of chemical compounds that target various aspects of lipid metabolism, particularly focusing on triglyceride synthesis, lipogenesis, and fatty acid metabolism. These inhibitors provide essential tools for understanding the role of TMEM68 in these processes. Inhibitors such as Atglistatin and Lipase Inhibitor, THL, which target triglyceride breakdown and lipase activity respectively, can provide insights into how triglyceride metabolism is regulated and how it might be interconnected with TMEM68 activity. Compounds affecting fatty acid synthesis and metabolism, like Triacsin C Solution in DMSO, C75 (racemic), and Cerulenin (synthetic), are critical for exploring the role of TMEM68 in lipogenesis and glycerolipid composition.
PPAR agonists and antagonists, such as Pioglitazone, Fenofibrate, and GW 9662, offer a means to study the regulation of lipid metabolism pathways that may be influenced by TMEM68's activity. In summary, the use of these inhibitors is key for investigating the role of TMEM68 in lipid metabolism, including triglyceride synthesis and the regulation of glycerolipid levels. By studying the effects of these compounds on TMEM68-associated pathways, researchers can gain a better understanding of the biological processes in which TMEM68 is involved and its potential significance in metabolic regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Atglistatin | 1469924-27-3 | sc-503147 | 5 mg | $330.00 | ||
Atglistatin selectively inhibits adipose triglyceride lipase (ATGL), potentially affecting triglyceride metabolism and indirectly influencing TMEM68's role. | ||||||
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $51.00 | 7 | |
Lipase Inhibitor, THL is a lipase inhibitor, primarily targeting pancreatic lipases, and may indirectly affect the metabolic pathways involving TMEM68. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $149.00 $826.00 | 14 | |
Triacsin C inhibits acyl-CoA synthetase, potentially impacting fatty acid metabolism and processes regulated by TMEM68. | ||||||
C75 (racemic) | 191282-48-1 | sc-202511 sc-202511A sc-202511B | 1 mg 5 mg 10 mg | $71.00 $202.00 $284.00 | 9 | |
C75 (racemic) is a fatty acid synthase inhibitor, potentially affecting de novo lipogenesis and pathways where TMEM68 is involved. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $115.00 $337.00 | 3 | |
Betulinic Acid inhibits stearoyl-CoA desaturase, which could influence fatty acid composition and TMEM68-mediated processes. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
Pioglitazone is a PPARγ agonist, influencing lipid metabolism and potentially affecting TMEM68-related pathways. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
AICAR activates AMPK, potentially influencing lipid metabolism and processes related to TMEM68's function. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $40.00 | 9 | |
Fenofibrate, a PPARα agonist, affects lipid metabolism and could indirectly influence TMEM68-related pathways. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $68.00 | 30 | |
GW9662 is a PPARγ antagonist, potentially affecting lipid storage and metabolism processes relevant to TMEM68. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Simvastatin inhibits HMG-CoA reductase, affecting cholesterol synthesis and potentially influencing lipid pathways associated with TMEM68. | ||||||